Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1980-10-21
|
| pubmed:abstractText |
Peripheral plasma from four postmenopausal women was analysed for estrone, estradiol, lutenizing hormone and follicle stimulating hormone during 24 hours following an oral intake of a single dose of 1.0 mg micronized estradiol, on the first day of therapy and after one month. A similar study was carried out with another four postmenopausal patients, who received 0.2 mg estradiol three times daily. The measurements were performed by radioimmunoassay (RIA). It is concluded that the plasma concentrations of estrone and estradiol are higher and those of FSH lower after one month of therapy than on the first treatment day, while plasma LH remains unchanged. Micronized estradiol is rapidly absorbed from the gastrointestinal tract and converted to estrone, and the plasma profiles of estrone during the day are more constant with a divided daily dose than with a single higher dose. The divided daily dose results in an equally good clinical effect even though the total administration of estradiol is lower.
|
| pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Acceptor Characteristics,
http://linkedlifedata.com/resource/pubmed/keyword/Age Factors,
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive...,
http://linkedlifedata.com/resource/pubmed/keyword/Demographic Factors,
http://linkedlifedata.com/resource/pubmed/keyword/Endocrine System,
http://linkedlifedata.com/resource/pubmed/keyword/Estradiol--administraction and dosage,
http://linkedlifedata.com/resource/pubmed/keyword/Estradiol--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Estrogens,
http://linkedlifedata.com/resource/pubmed/keyword/Estrone--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/Follicle Stimulating Hormone,
http://linkedlifedata.com/resource/pubmed/keyword/Gonadotropins,
http://linkedlifedata.com/resource/pubmed/keyword/Gonadotropins, Pituitary,
http://linkedlifedata.com/resource/pubmed/keyword/Hormones,
http://linkedlifedata.com/resource/pubmed/keyword/Luteinizing Hormone--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Menopause,
http://linkedlifedata.com/resource/pubmed/keyword/Metabolic Effects,
http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives--pharmacodynamics,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Population,
http://linkedlifedata.com/resource/pubmed/keyword/Population Characteristics,
http://linkedlifedata.com/resource/pubmed/keyword/Reproduction,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Steroid Metabolic Effects
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0001-6349
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
59
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
149-53
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:otherAbstract |
PIP: Since unopposed estrogen therapy, as well as overly high doses, has been implicated in increasing the risk for endometrial cancer, this study tried to determine the effect of reducing the daily amount of estrogen and dividing that reduced dosage into 3 daily doses. Hence, the metabolism and pharmacokinetics of micronized estradiol were studied by analyzing the peripheral plasma of 4 postmenopausal women for estrone, estradiol, luteinizing hormone, and follicle stimulating hormone during the 24 hours after oral ingestion of a single dose of 1 mg of micronized estradiol at the beginning of treatment and after 1 month's treatment. 4 other postmenopausal patients were studied similarly but they were given .2 mg of estradiol 3 times daily. Various radioimmunoassays were used for hormone determinations in plasma. Plasma concentration of estrone and estradiol were higher, and follicle stimulating hormone levels lower, after 1 month of therapy than on the first day of treatment; plasma luteinizing hormone remained unchanged. Since micronized estradiol is rapidly metabolized to estrone, the divided (3 times) daily doses provided a more constant estrone profile than the single daily dose. Both subjective and objective clinical effects were as good or better on the divided daily dose, although the amount of estradiol received was less.
|
| pubmed:meshHeading |
pubmed-meshheading:6773291-Administration, Oral,
pubmed-meshheading:6773291-Estradiol,
pubmed-meshheading:6773291-Estrone,
pubmed-meshheading:6773291-Female,
pubmed-meshheading:6773291-Follicle Stimulating Hormone,
pubmed-meshheading:6773291-Humans,
pubmed-meshheading:6773291-Kinetics,
pubmed-meshheading:6773291-Luteinizing Hormone,
pubmed-meshheading:6773291-Menopause,
pubmed-meshheading:6773291-Middle Aged,
pubmed-meshheading:6773291-Radioimmunoassay,
pubmed-meshheading:6773291-Time Factors
|
| pubmed:year |
1980
|
| pubmed:articleTitle |
Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.
|
| pubmed:publicationType |
Journal Article
|